Skip to main content

Table 3 Univariate and multivariable analysis of OS and RFS in oropharyngeal and non-oropharyngeal patients

From: Systemic inflammation is an independent predictive marker of clinical outcomes in mucosal squamous cell carcinoma of the head and neck in oropharyngeal and non-oropharyngeal patients

  Overall survival Recurrence free survival
Variable Univariate, HR (95 % CI) p value* Multivariable, HR (95 % CI) p value** Univariate, HR (95 % CI) p value* Multivariable, HR (95 % CI) p value**
Oropharyngeal patients (n = 76)a  
 Age (continuous) 1.07 (1.01-1.12) 0.03 1.03 (0.97-1.10) 0.3 1.05 (1.00-1.10) 0.08 1.02 (0.97-1.08) 0.4
 Sex (males vs females) No females died No females had recurrence
 ECOG PS (0 vs 1–2) 4.08 (1.38-12.12) <0.01 4.36 (1.18-16.06) 0.03 3.33 (1.24-8.89) 0.01 2.92 (0.95-8.97) 0.07
 Smoking status   <0.01   0.2   0.03   0.3
 (current smokerb vs non-smoker) 0.17 (0.04-0.70)   0.34 (0.07-1.64)   0.31 (0.01-0.98)   0.53 (0.15-1.88)  
 (current smokerb vs ex-smoker) 0.22 (0.07-0.80)   0.28 (0.07-1.09)   0.28 (0.09-0.85)   0.40 (0.12-1.31)  
 AJCC stage (I-II vs III-IV) 0.78 (0.26-2.34) 0.7 -   0.82 (0.31-2.19) 0.7 -  
 Treatment (CRT and CRT + surgery vs RT and RT + surgery) 0.50 (0.46-4.93) 0.5 -   0.63 (0.32-4.00) 0.6 -  
 NLR (≤5 vs > 5) 4.96 (1.66-14.80) <0.01 4.60 (1.26-16.80) 0.02 3.50 (1.38-8.90) <0.01 3.01 (1.07-8.45) 0.04
Non-oropharyngeal patients (n = 69)c  
 Age (continuous) 1.02 (0.99-1.06) 0.8 -   1.01 (0.98-1.032) 0.9 -  
 Sex (males vs females) 1.05 (0.38-2.87) 0.9 -   0.81 (0.33-1.96) 0.6 -  
 ECOG PS (0 vs 1–2) 3.37 (1.36-8.37) <0.01 2.57 (0.98-6.76) 0.04 1.66 (0.82-3.36) 0.2 1.49 (0.70-3.21) 0.2
 Smoking status   0.04   <0.001   0.02   <0.001
 (current smokerb vs non-smoker) 0.18 (0.04-0.79)   0.16 (0.03-0.76)   0.35 (0.14-0.87)   0.35 (0.14-0.90)  
 (current smokerb vs ex-smoker) 0.56 (0.22-1.44)   0.34 (0.12-0.94)   0.38 (0.16-0.90)   0.32 (0.13-0.79)  
 AJCC stage (I-II vs III-IV) 1.43 (0.56-3.70) 0.5 -   1.53 (0.68-3.42) 0.3 -  
 Treatment (CRT and CRT + surgery vs RT and RT + surgery) 0.85 (0.46-2.57) 0.8 -   1.01 (0.50-2.05) 1 -  
 NLR (≤5 vs > 5) 3.32 (1.36-8.10) <0.01 3.64 (1.34-9.87) 0.02 1.76 (0.79-3.96) 0.2 2.02 (0.83-4.91) 0.1
  1. Abbreviations: HR hazard ratio, ECOG PS Eastern Cooperative Oncology Group performance status, AJCC American Joint Committee on Cancer, CRT chemoradiotherapy, RT radiotherapy and NLR neutrophil-to-lymphocyte ratio
  2. *, p value from Kaplan-Meier logrank test; **, p value from Cox regression log likelihood ratio test; a, one patient missing smoking status; b, referent group; and c, missing 3 patients (two patients missing smoking status and one patient missing ECOG status).